Interleukin-8 and soluble intercellular adhesion molecule 1 during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment

Scott Sinclair, E. B. Golden, P. Carratu, B. E. John, Reba Umberger, Gianfranco Meduri

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aim. Interleukin-8 (IL-8) and intercellular adhesion molecule-1 (ICAM-1) promote migration and activation of neutrophils in the lung. We investigated the longitudinal relationship between circulating and bronchoalveolar lavage (BAL) levels of IL-8 and sICAM-1 during acute respiratory distress syndrome (ARDS) and in response to prolonged methylprednisolone (MP) treatment. Design. Prospective observational study, and prospective double-blind placebo controlled randomized study. Setting: University Medical Center. Methods. We studied 28 29 medical and surgical patients with ARDS. A reduction in lung injury score (LIS) > 1 point from day 1 to day 7 of ARDS divided patients into improvers (group 1, n=7) and nonimprovers (n=21). Nonim-provers included those (group 2, n=17) randomized to MP treatment vs placebo, and those who died prior to ARDS day 10 (group 3, n=4). All improvers survived. Interventions: We obtained serial measurements of plasma and BAL IL-8 and sICAM-1 levels, and components of the LIS. Results. At ARDS onset, improvers had lower IL-8 levels in the plasma and lower sICAM-1 levels in plasma and BAL. By ARDS day 10, plasma IL-8 remained persistently elevated in nonimprovers but declined in improvers (p<0.0001); whereas plasma sICAM-1 levels increased in nonimprovers (p<0.0001). BAL IL-8 levels correlated with BAL neutrophilia (r=0.56624, p= 0.02). MP treatment was associated with a reduction in IL-8 and sICAM-1 levels in plasma (by day 5, p<0.0001) and BAL (by days 8-15, p<0.0001). Conclusion. We provide additional evidence for the biological efficacy of MP treatment in unresolving ARDS.

Original languageEnglish (US)
Pages (from-to)93-103
Number of pages11
JournalMinerva Pneumologica
Volume45
Issue number2
StatePublished - Jun 1 2006

Fingerprint

Adult Respiratory Distress Syndrome
Methylprednisolone
Intercellular Adhesion Molecule-1
Interleukin-8
Bronchoalveolar Lavage
Lung Injury
Therapeutics
Placebos
Neutrophil Activation
Observational Studies
Prospective Studies
Lung

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

@article{d6075bd8768d4408a95b0ae2d0112541,
title = "Interleukin-8 and soluble intercellular adhesion molecule 1 during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment",
abstract = "Aim. Interleukin-8 (IL-8) and intercellular adhesion molecule-1 (ICAM-1) promote migration and activation of neutrophils in the lung. We investigated the longitudinal relationship between circulating and bronchoalveolar lavage (BAL) levels of IL-8 and sICAM-1 during acute respiratory distress syndrome (ARDS) and in response to prolonged methylprednisolone (MP) treatment. Design. Prospective observational study, and prospective double-blind placebo controlled randomized study. Setting: University Medical Center. Methods. We studied 28 29 medical and surgical patients with ARDS. A reduction in lung injury score (LIS) > 1 point from day 1 to day 7 of ARDS divided patients into improvers (group 1, n=7) and nonimprovers (n=21). Nonim-provers included those (group 2, n=17) randomized to MP treatment vs placebo, and those who died prior to ARDS day 10 (group 3, n=4). All improvers survived. Interventions: We obtained serial measurements of plasma and BAL IL-8 and sICAM-1 levels, and components of the LIS. Results. At ARDS onset, improvers had lower IL-8 levels in the plasma and lower sICAM-1 levels in plasma and BAL. By ARDS day 10, plasma IL-8 remained persistently elevated in nonimprovers but declined in improvers (p<0.0001); whereas plasma sICAM-1 levels increased in nonimprovers (p<0.0001). BAL IL-8 levels correlated with BAL neutrophilia (r=0.56624, p= 0.02). MP treatment was associated with a reduction in IL-8 and sICAM-1 levels in plasma (by day 5, p<0.0001) and BAL (by days 8-15, p<0.0001). Conclusion. We provide additional evidence for the biological efficacy of MP treatment in unresolving ARDS.",
author = "Scott Sinclair and Golden, {E. B.} and P. Carratu and John, {B. E.} and Reba Umberger and Gianfranco Meduri",
year = "2006",
month = "6",
day = "1",
language = "English (US)",
volume = "45",
pages = "93--103",
journal = "Minerva Pneumologica",
issn = "0026-4954",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Interleukin-8 and soluble intercellular adhesion molecule 1 during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment

AU - Sinclair, Scott

AU - Golden, E. B.

AU - Carratu, P.

AU - John, B. E.

AU - Umberger, Reba

AU - Meduri, Gianfranco

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Aim. Interleukin-8 (IL-8) and intercellular adhesion molecule-1 (ICAM-1) promote migration and activation of neutrophils in the lung. We investigated the longitudinal relationship between circulating and bronchoalveolar lavage (BAL) levels of IL-8 and sICAM-1 during acute respiratory distress syndrome (ARDS) and in response to prolonged methylprednisolone (MP) treatment. Design. Prospective observational study, and prospective double-blind placebo controlled randomized study. Setting: University Medical Center. Methods. We studied 28 29 medical and surgical patients with ARDS. A reduction in lung injury score (LIS) > 1 point from day 1 to day 7 of ARDS divided patients into improvers (group 1, n=7) and nonimprovers (n=21). Nonim-provers included those (group 2, n=17) randomized to MP treatment vs placebo, and those who died prior to ARDS day 10 (group 3, n=4). All improvers survived. Interventions: We obtained serial measurements of plasma and BAL IL-8 and sICAM-1 levels, and components of the LIS. Results. At ARDS onset, improvers had lower IL-8 levels in the plasma and lower sICAM-1 levels in plasma and BAL. By ARDS day 10, plasma IL-8 remained persistently elevated in nonimprovers but declined in improvers (p<0.0001); whereas plasma sICAM-1 levels increased in nonimprovers (p<0.0001). BAL IL-8 levels correlated with BAL neutrophilia (r=0.56624, p= 0.02). MP treatment was associated with a reduction in IL-8 and sICAM-1 levels in plasma (by day 5, p<0.0001) and BAL (by days 8-15, p<0.0001). Conclusion. We provide additional evidence for the biological efficacy of MP treatment in unresolving ARDS.

AB - Aim. Interleukin-8 (IL-8) and intercellular adhesion molecule-1 (ICAM-1) promote migration and activation of neutrophils in the lung. We investigated the longitudinal relationship between circulating and bronchoalveolar lavage (BAL) levels of IL-8 and sICAM-1 during acute respiratory distress syndrome (ARDS) and in response to prolonged methylprednisolone (MP) treatment. Design. Prospective observational study, and prospective double-blind placebo controlled randomized study. Setting: University Medical Center. Methods. We studied 28 29 medical and surgical patients with ARDS. A reduction in lung injury score (LIS) > 1 point from day 1 to day 7 of ARDS divided patients into improvers (group 1, n=7) and nonimprovers (n=21). Nonim-provers included those (group 2, n=17) randomized to MP treatment vs placebo, and those who died prior to ARDS day 10 (group 3, n=4). All improvers survived. Interventions: We obtained serial measurements of plasma and BAL IL-8 and sICAM-1 levels, and components of the LIS. Results. At ARDS onset, improvers had lower IL-8 levels in the plasma and lower sICAM-1 levels in plasma and BAL. By ARDS day 10, plasma IL-8 remained persistently elevated in nonimprovers but declined in improvers (p<0.0001); whereas plasma sICAM-1 levels increased in nonimprovers (p<0.0001). BAL IL-8 levels correlated with BAL neutrophilia (r=0.56624, p= 0.02). MP treatment was associated with a reduction in IL-8 and sICAM-1 levels in plasma (by day 5, p<0.0001) and BAL (by days 8-15, p<0.0001). Conclusion. We provide additional evidence for the biological efficacy of MP treatment in unresolving ARDS.

UR - http://www.scopus.com/inward/record.url?scp=33750176031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750176031&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 93

EP - 103

JO - Minerva Pneumologica

JF - Minerva Pneumologica

SN - 0026-4954

IS - 2

ER -